ABVD and BEACOPP regimens’ efects on fertility in young males with Hodgkin lymphoma

• M. S. A. Amin ^[2] ; O. Brunckhorst ^[2] ; D. Wrench ^[1] ; M. Gleeson ^[1] ; M. Kazmi ; K. Ahmed ^[2]
  1. [1] Guy's Hospital

     Guy's Hospital

     Reino Unido

     
  2. [2] MRC Centre for Transplantation, Guy’s Hospital Campus, King’s College London, King’s Health Partners, London SE1 9RT, UK
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 6, 2021, págs. 1067-1077
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Considering the increased cancer patient survivorship, the focus is now on addressing the impacts of treatment on quality of life. In young people, altered reproductive function is a major issue and its efects in young males are largely neglected by novel research. To improve clinician awareness, we systematically reviewed side efects of chemotherapy for Hodgkin lymphoma (HL) in young males.

    Methods The review was prospectively registered (PROSPERO N. CRD42019122868). Three databases (Medline via PUBMED, SCOPUS, and Cochrane Library) were searched for studies featuring males aged 13-51-years who underwent chemotherapy for HL using ABVD (Adriamycin® (doxorubicin), bleomycin, vinblastine, and dacarbazine) or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone) regimens. These chemotherapy regimens were compared against each other using sperm characteristics, FSH, and inhibin B levels to measure fertility levels.

    Results Data were extracted from fve studies featuring 1344 patients. 6 months post-ABVD saw marked deterioration in sperm count, further reduced by more cycles (P=0.05). Patients treated with BEACOPP rather than ABVD were more prone to oligospermia. Receiving fewer cycles of both regimens increased the likelihood of sperm production recovering. Patients treated with 6-8 cycles of BEACOPP did not recover spermiogenesis.

    Conclusions ABVD and BEACOPP regimens signifcantly reduce fertility function to varying efects depending on treatment duration. ABVD temporarily causes signifcant reductions in male fertility, whereas BEACOPP’s efects are more permanent. Therefore, clinicians should discuss fertility preservation with male patients receiving infertility-inducing gonadotoxic therapy. Further high-quality studies are required to more adequality describe the risk to fertility by chemotherapy.